Biosimilars: A New Generation of Biologics - Hardcover

9782817803357: Biosimilars: A New Generation of Biologics
Alle Exemplare der Ausgabe mit dieser ISBN anzeigen:
 
 
Reseña del editor:

Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the “generic rule” valid for small chemical entities.

 

In response, a dedicated regulation was issued in the European Union. It is based on the concept of “biological medicinal products similar to a biological reference product”, or “biosimilars”. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature.

 

This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context.

Biografía del autor:
Jean-Louis Prugnaud is a pharmacist, former head of pharmacy department at Saint-Antoine Hospital, Paris, France. He is Member of the French Commission of drugs’ distribution authorization, President of the Commission of gene and cellular therapy and President of the pharmaceutical working group on biological and biothechnological drugs. Jean-Hugues Trouvin works at AFSSAPS (French health products safety agency) and at the pharmaceutical and biological sciences department at the Paris Descartes University in Paris, France. Preface: Christian K. Schneider is Chairman, CHMP of the Similar Biological (Biosimilar) Medicinal Products Working Party (BMWP), member of the European Medicines Agency( London, United Kingdom) and works at the Paul-Ehrlich-Institut, Federal Agency for Sera and Vaccines (Langen, Germany) and at the Centre for Experimental and Clinical Infection Research (Hannover, Germany).

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Versand: EUR 48,99
Von Deutschland nach USA

Versandziele, Kosten & Dauer

In den Warenkorb

Weitere beliebte Ausgaben desselben Titels

9782817805146: Biosimilars: A New Generation of Biologics

Vorgestellte Ausgabe

ISBN 10:  2817805143 ISBN 13:  9782817805146
Verlag: Springer, 2014
Softcover

  • 9782817803418: Biosimilars: A New Generation of Biologics

    Springer, 2012
    Softcover

Beste Suchergebnisse beim ZVAB

Foto des Verkäufers

Prugnaud, Jean-Louis|Trouvin, Jean-Hugues
Verlag: Springer Paris (2012)
ISBN 10: 2817803353 ISBN 13: 9782817803357
Neu Hardcover Anzahl: > 20
Anbieter:
moluna
(Greven, Deutschland)
Bewertung

Buchbeschreibung Zustand: New. Artikel-Nr. 4315299

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 107,09
Währung umrechnen

In den Warenkorb

Versand: EUR 48,99
Von Deutschland nach USA
Versandziele, Kosten & Dauer
Foto des Verkäufers

Jean-Hugues Trouvin
Verlag: Springer Paris (2012)
ISBN 10: 2817803353 ISBN 13: 9782817803357
Neu Hardcover Anzahl: 1
Anbieter:
AHA-BUCH GmbH
(Einbeck, Deutschland)
Bewertung

Buchbeschreibung Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the 'generic rule' valid for small chemical entities. In response, a dedicated regulation was issued in the European Union. It is based on the concept of 'biological medicinal products similar to a biological reference product', or 'biosimilars'. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature. This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context. Artikel-Nr. 9782817803357

Weitere Informationen zu diesem Verkäufer | Verkäufer kontaktieren

Neu kaufen
EUR 129,93
Währung umrechnen

In den Warenkorb

Versand: EUR 32,99
Von Deutschland nach USA
Versandziele, Kosten & Dauer